Online inquiry

IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9531MR)

This product GTTS-WQ9531MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLH1 gene. The antibody can be applied in Prostate Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2346
UniProt ID Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9531MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4119MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ1219MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ11252MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ10848MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ5354MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8814MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ7917MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK3196165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW